Back to research feed

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

August 3, 2026 · via Europe PMC

Sarcomas With EWSR1::NFATC2 and FUS::NFATC2 Gene Fusions Arising in Soft Tissue and Bone: A Clinicopathologic Study of 32 Cases Emphasizing Their Wide Morphologic and Clinical Spectrum.

Torres-Mora J, Dehner CA, Warmke LM, +15 more, Fritchie KJ.

Journal ArticleAbstract only — full text under license

AI summary — for doctors, generated from the abstract only

NFATC2-rearranged sarcomas have a wide morphologic range, often indolent but with metastasis in some, and higher-grade features may predict worse behavior.

What was studied

Clinicopathologic case series of 32 sarcomas with EWSR1::NFATC2 (25) or FUS::NFATC2 (7) fusions in soft tissue and bone.

Key findings

  • EWSR1::NFATC2 tumors arose in soft tissue (16) and bone (8); distant metastases occurred in 6 of 19 with follow-up.
  • FUS::NFATC2 tumors were only in bone, with local recurrence in 2 and lung metastases in 2 of 6 patients.
  • Low-grade tumors had fewer adverse events than high-grade (P = .026) on a 2-tier grading scheme.

Clinical relevance

It helps pathologists recognize this entity and offers early prognostic clues.

Who should care

Pathology

Limitations

Small series with short, incomplete follow-up (median about 2 years), so metastasis-free survival differences were not statistically supported.

Consider NFATC2 fusion testing for unclassified round or spindle cell sarcomas and expect a possibly protracted course.

This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.

Abstract

Bone and soft tissue sarcomas harboring EWSR1::NFATC2 and FUS::NFATC2 fusions (NFATC2-rearranged sarcomas) are a recently defined entity with a morphologic spectrum and clinical behavior that are not fully elucidated. We studied 32 such sarcomas that occurred in 21 male and 11 female patients. The EWSR1::NFATC2 fusion was found in tumors of 25 patients (17 men and 8 women; median age, 40 years; range, 14-78 years), 16 of which arose in soft tissue, while 8 originated in the bone. Morphologically, they showed relatively consistent morphologic features yet variable degrees of cytologic atypia, mitotic rates, and necrosis. Follow-up (19 patients; median, 22 months; range, 1-70 months) demonstrated local recurrence in 3 patients, while distant metastases occurred in 6 patients. Two patients died of disease, 4 were alive with disease, and 13 were alive without evidence of disease. In contrast, the FUS::NFATC2 fusion was exclusively seen in osseous tumors, which occurred in 7 patients (4 men and 3 women; median age, 32 years; range, 4-62 years). Further, FUS::NFATC2 tumors showed significant morphologic heterogeneity. Follow-up (6 patients; median, 18 months; range, 13-60 months) demonstrated local recurrence in 2 patients and lung metastases in 2 patients. At the last follow-up, 3 patients were alive with disease, while 3 patients were alive without evidence of disease. Using a 2-tiered grading scheme based on cytologic atypia, mitotic rate, and necrosis, patients with low-grade tumors experienced significantly fewer adverse events than those with high-grade tumors (P = .026); however, estimated metastasis-free survival was not statistically significant due to our limited sample size. Overall, our study expands on the morphologic spectrum of NFATC2-rearranged sarcomas and highlights the clinicopathologic, molecular, and genetic differences between the EWSR1- and FUS-rearranged tumors. Although additional long-term follow-up data are required, our study further suggests that a subset of these sarcomas have a protracted clinical course, while high-grade morphologic features such as atypia, mitotic activity, and necrosis may correlate with worse behavior.

DOI

10.1016/j.modpat.2026.101050

PMID

42547032

Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.

Want more like this?

Browse more from the feed. A free account unlocks the full feed, saving and communities.

Back to the research feed

Create a free account · Sign in